- Home
- RDN vs GH Comparison
RDN vs GH Comparison
Compare RDN & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDN | GH |
|---|---|---|
| Founded | 1977 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 13.2B |
| IPO Year | 1992 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RDN | GH |
|---|---|---|
| Price | $33.03 | $112.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 21 |
| Target Price | $40.00 | ★ $101.86 |
| AVG Volume (30 Days) | 1.1M | ★ 1.9M |
| Earning Date | 02-04-2026 | 02-19-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | ★ 3.60 | N/A |
| EPS | ★ 4.00 | N/A |
| Revenue | ★ $1,273,225,000.00 | $902,569,000.00 |
| Revenue This Year | N/A | $35.00 |
| Revenue Next Year | $2.72 | $26.80 |
| P/E Ratio | $8.37 | ★ N/A |
| Revenue Growth | 2.49 | ★ 30.38 |
| 52 Week Low | $29.32 | $34.88 |
| 52 Week High | $38.84 | $113.91 |
Technical Indicators
Market Signals| Indicator | RDN | GH |
|---|---|---|
| Relative Strength Index (RSI) | 35.14 | 64.96 |
| Support Level | $31.51 | $103.80 |
| Resistance Level | $33.37 | $113.91 |
| Average True Range (ATR) | 0.90 | 5.02 |
| MACD | -0.43 | 0.47 |
| Stochastic Oscillator | 30.25 | 83.27 |
Price Performance
Historical ComparisonAbout RDN Radian Group Inc.
Radian Group Inc is engaged in mortgage and real estate services. It provides both credit-related mortgage insurance coverage and other products and services across the residential real estate and mortgage finance industries. It has one business segment Mortgage Insurance. The Mortgage Insurance segment aggregates, manages, and distributes U.S. mortgage credit risk for the benefit of mortgage lending institutions and mortgage credit investors, through private mortgage insurance on residential first-lien mortgage loans, and also offers other credit risk management solutions, including contract underwriting, to customers. It also provides other mortgage and real estate products and services through Mortgage Conduit, Title, Real Estate Services, and Real Estate Technology businesses.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.